Compugen IND Application for Triple Combination Study Cleared by the US FDA
The U.S. Food and Drug Administration has cleared Compugen’s (CGEN) investigational new drug (IND) application for its Phase 1/2 study evaluating the triple combination of COM701, Compugen’s first-in-class anti-PVRIG antibody, OPDIVO® (nivolumab) -- Bristol Myers . . .
This content is for paid subscribers.
Impacting News June 1, 2020